Parow Entheobiosciences

Parow Entheobiosciences is a pre-clinical stage biotechnology company focused on developing entheogen-based therapeutics for psychiatric and neurological disorders, including obsessive-compulsive disorder (OCD), depression, and PTSD. The company leverages the neuroplastic potential of full-spectrum psychoactive molecules and novel synthetic analogues. In partnership with Back of the Yards Algae Sciences (BYAS), Parow has pioneered cell-based, cruelty-free methods to produce entheogenic compounds, such as 5-MeO-DMT from immortalized toad parotoid gland cells. Its pipeline includes natural psychedelic mushroom extracts (PME) and novel psychedelic-derived new chemical entities (PD-NCEs) like HBL20017, a putatively non-hallucinogenic serotonin receptor agonist, and HBL20016, a hallucinogenic analogue, both being evaluated for anti-obsessional efficacy.